You are here: Industry Insights > grunenthal

News List

Grünenthal Acquires Mestex AG and it's Phase-III-Ready Investigational Medicine MTX-071 for the Treatment of Pain Associated with Osteoarthritis of the Knee americanpharmaceuticalreview
April 13, 2021
Grünenthal has announced the acquisition of Mestex AG through the takeover of all of its shares and options. Mestex AG is a Swiss biotech company that has developed the innovative investigational medicine MTX-071 (resiniferatoxin) for the ...
Peripheral NOP Agonist Addressing Chronic Peripheral Neuropathic Pain Enters Clinical Development americanpharmaceuticalreview
January 06, 2021
Grünenthal announced the first participants have been enrolled in a Phase I trial of a peripherally restricted Nociceptin/orphanin peptide receptor (NOP) agonist, an oral investigational medicine with a unique mechanism of action for the treatment of ...
AZ sells rights to statin med Crestor to Grünenthal pharmatimes
December 01, 2020
AstraZeneca (AZ) has announced that it will sell the rights to statin medication Crestor to Grünenthal in over 30 European countries.
Grünenthal, Averitas Announce FDA Approval of QUTENZA for Neuropathic Pain americanpharmaceuticalreview
July 29, 2020
Grünenthal announced its U.S. subsidiary Averitas Pharma, received U.S. Food and Drug Administration (FDA) approval for QUTENZA® (capsaicin) 8% patch for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet...
Grunenthal Acquires Averitas Pharmal and Establishes Commercial Footprint in the US pharmafocusasia
November 26, 2018
Grünenthal announced today that it has acquired the US-based pharmaceutical company Averitas Pharma, thereby extending its commercial ....
Grunenthal establishes commercial footprint in the US biospectrumasia
November 19, 2018
Averitas Pharma will be commercialising the pain patch Qutenza (8% capsaicin) for Grunenthal in the US.
Grunenthal establishes commercial footprint in the US biospectrumasia
November 15, 2018
Averitas Pharma will be commercialising the pain patch Qutenza (8% capsaicin) for Grunenthal in the US.
Agreement with Grünenthal for rights to Nexium in Europe and Vimovo worldwide (ex-US) worldpharmanews
October 31, 2018
AstraZeneca has agreed to divest the prescription medicine rights to Nexium (esomeprazole) in Europe, as well as the global rights (excluding the US and Japan) to Vimovo (naproxen/esomeprazole) to Grünenthal.
Mundipharma signs Chinese licensing and distribution agreement with Grünenthal pharmafile
January 17, 2018
US-based firm Mundipharma is set to take over commercialisation and distribution duties for the analgesic Tramal (tramadol) in China on behalf of Grünenthal, it has emerged.
Grunenthal and Mundipharma enter commercial partnership in China prnasia
January 16, 2018
Grunenthal and Mundipharma announced today that they've entered into a License and Distribution Agreement.

Previous page 1 2 Next page